Ossium Health Breaks into the Orthopedics Market

The first patient has been treated with Ossium Health’s OssiGraft™ viable bone matrix allograft.

San Francisco, California, United States – December 14, 2023 /MarketersMEDIA/ —

There’s a new player in the competitive orthopedic biologics market. This week, Ossium Health announced that a patient has been treated with its newly released viable bone matrix allograft, OssiGraft™, a product that is raising the bar for tissue product safety.

Since the company’s founding in 2016, Ossium has focused on areas outside of orthopedic products, namely establishing and growing its first-of-its-kind bone marrow bank sourced from organ donors. The goal of its bone marrow bank is to expand patient access to transplantable bone marrow, complementing the existing living donor registry. Earlier this year, Ossium announced the launch of a clinical trial of their bone marrow in blood cancer patients.

Ossium is now expanding into a complementary field with the launch of OssiGraft, its viable bone matrix allograft used in orthopedic surgery to repair, replace, or reconstruct bone defects. The company made this possible through an innovative adaptation to their bone marrow production method, which now allows them to produce both bone marrow and OssiGraft from the same donor tissue.

“The introduction of OssiGraft is an integral part of Ossium’s broader mission of improving the health, vitality, and longevity of human beings,” explained Kevin Caldwell, Ossium’s CEO, Co-Founder & President. “With OssiGraft, we’re helping patients with skeletal tissue damage restore their quality of life.”

According to orthopedic surgeons Dr. Jason Piraino and Dr. Thomas Roukis, OssiGraft offers significant safety advantages. As a cell therapy manufacturer, Ossium maintains stringent screening, testing, and processing controls – which are required and expected for their bone marrow product – far exceeding regulatory requirements for tissue products. “I have an additional layer of confidence with OssiGraft because of its superior graft source, thorough decontamination, and extensive testing,” said Dr. Piraino. 

Another major selling point for surgeons is OssiGraft’s handling properties. Dr. Piraino described the product as having “handling characteristics [that] are unique and superior to any graft on the market.” He continued, “its versatility in a variety of cases and ability to combine with antibiotics or bone marrow aspirate make this graft exceptional.”

Ossium is currently expanding distribution of OssiGraft to hospitals across the US while developing a next-generation orthopedic product that they plan to introduce next year.

Contact Info:
Name: Geney Park
Email: Send Email
Organization: Ossium Health
Website: http://ossiumhealth.com

Release ID: 89113339

If there are any deficiencies, discrepancies, or concerns regarding the information presented in this press release, we kindly request that you promptly inform us by contacting error@releasecontact.com. Our dedicated team is committed to addressing any identified issues within 8 hours to guarantee the delivery of accurate and reliable content to our esteemed readers.